{
    "clinical_study": {
        "@rank": "94291", 
        "brief_summary": {
            "textblock": "To determine the safety of and immune response to vaccinia-derived HIV-1 recombinant\n      envelope glycoprotein (gp160) at a dose of 200 mcg in human volunteers; to evaluate duration\n      of antibody response and its relationship to the dose and frequency of inoculation.\n\n      Although recent advances have been made in antiviral therapy against AIDS, there is\n      currently no cure for AIDS. It is likely that the ultimate control of the disease depends on\n      the development of safe and effective vaccines against HIV."
        }, 
        "brief_title": "A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose", 
        "completion_date": {
            "#text": "October 1994", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "HIV Infections", 
                "Immunologic Deficiency Syndromes", 
                "Vaccinia"
            ]
        }, 
        "detailed_description": {
            "textblock": "Although recent advances have been made in antiviral therapy against AIDS, there is\n      currently no cure for AIDS. It is likely that the ultimate control of the disease depends on\n      the development of safe and effective vaccines against HIV.\n\n      Healthy, adult volunteers without identifiable high-risk behavior for HIV-1 infection are\n      randomly assigned to receive three injections of either 200 mcg gp160 vaccine or a placebo.\n      At each participating site, four volunteers receive vaccine and two volunteers receive\n      placebo. Primary immunization and two booster immunizations at day 30 and day 180 are done\n      in an outpatient setting. Volunteers are closely monitored for the first 2 weeks\n      postimmunization (primary and boosters), and extensively followed for 2 years. Volunteers\n      may be offered an additional booster of the same preparation at 12 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must be:\n\n          -  Normal, healthy, HIV-negative adults who fully comprehend the purpose and details of\n             the study.\n\n          -  Available for 2 years of follow-up.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following conditions or symptoms are excluded:\n\n          -  History of positive PPD (tuberculin test) and abnormal chest x-ray.\n\n          -  Positive syphilis serology (e.g., RPR).\n\n          -  Positive for circulating hepatitis B surface antigen.\n\n        Patients with the following are excluded:\n\n          -  They or their sexual partners have identifiable high-risk behavior for HIV infection.\n\n          -  History of immunodeficiency or chronic illness.\n\n          -  Evidence of psychological or psychiatric problems that may lead to noncompliance.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Immunosuppressive medications.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Blood transfusions or cryoprecipitates within the past 6 months."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001056", 
            "org_study_id": "AVEG 004A", 
            "secondary_id": "10544"
        }, 
        "intervention": {
            "intervention_name": "gp160 Vaccine (Immuno-AG)", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Krestin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Vaccines, Synthetic", 
            "Vaccinia Virus", 
            "Viral Vaccines", 
            "HIV-1", 
            "HIV Envelope Protein gp160", 
            "AIDS Vaccines", 
            "HIV Seronegativity", 
            "HIV Preventive Vaccine"
        ], 
        "lastchanged_date": "April 26, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63104"
                    }, 
                    "name": "St. Louis Univ. School of Medicine AVEG"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14642"
                    }, 
                    "name": "Univ. of Rochester AVEG"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "Vanderbilt Univ. Hosp. AVEG"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg Dose", 
        "overall_official": {
            "last_name": "Belshe R", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "PMID": "9310283", 
            "citation": "Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, Verani-Ketter N, Erb S, Smith CM, Belshe RB, Wagner LJ, McElrath MJ, Schwartz DH, Fast P. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses. 1997 Sep 20;13(14):1163-77."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001056"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "Immuno-US", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2012"
    }, 
    "geocoordinates": {
        "St. Louis Univ. School of Medicine AVEG": "38.627 -90.199", 
        "Univ. of Rochester AVEG": "43.161 -77.611", 
        "Vanderbilt Univ. Hosp. AVEG": "36.166 -86.784"
    }
}